Dr. Clay Siegell has done a lot for the community in his cancer research. As the CEO of Seattle Genetics, he has a responsibility to innovate and find new ways to help people cope with and conquer major illnesses. The latest accomplishment that Seattle Genetics experienced was a fast-track FDA approval of a drug that they created to limit cancer progress. The name of the drug is Adcetris, and it could bring brighter days to people who have lymphoma.
Adcetris is a drug that people can use if they have already tried other treatments such as chemotherapy, stem cell transplants, or other types of cancer medication. It’s a drug that helps the person ward off cancer by interfering with its growth processes. The drug has been doing fairly well in the industry in that it has helped numerous people. Seattle Genetics will continue to work on solutions that can reverse or pause illnesses such as lymphoma.
Clay Siegall received his B.S at the University of Mary and his PhD at George Washington University. Dr. Siegall sat on several boards such as the Ultragenyx Pharmaceutical Inc. and the Alder Biopharmaceuticals, Inc. His work goes far beyond those experiences, however. He has an extensive profile that shows endless years of dedication to people’s welfare. Dr. Siegall is constantly trying to come up with new ways to help people regenerate their health. With his skills and accolades, he continues to research and discover new solutions to the modern abnormalities of the human body.